Kala Bio Inc
KALABuild a strategy around KALA
Kala Bio Inc AI Insights
Informational only. Not investment advice.Snapshot
- Zero revenue TTM with -36.1M operating loss and only 21.1M cash remaining - runway under 8 months at current burn rate of -32M/year[Cash and Equivalents]
- Negative equity of -8.7M with 30M total debt (28.4M current) creates immediate refinancing crisis[Common Stockholders Equity]
- R&D spend of 23.7M TTM is 66% of operating expenses - pre-commercial biotech with no approved products generating revenue[Research and Development TTM]
Watch Triggers
- Cash and Equivalents: Falls below 15M or no financing announced within 90 days — Sub-6-month runway triggers going concern and accelerates debt covenants
- Total Revenue TTM: Any revenue recognition from licensing or product sales — First revenue validates pipeline and extends runway without dilution
- Shares Outstanding: Increases >50% from current 7M shares — Signals distressed financing terms destroying per-share value
Bull Case
Micro-cap (4.2M market cap) with 13.1M EV creates asymmetric upside if pipeline advances - single positive trial could 10x valuation
R&D of 23.7M TTM demonstrates active pipeline development; potential licensing/partnership value exceeds current EV
Bear Case
Negative equity (-8.7M) with 30M debt and zero revenue = textbook insolvency risk. Current liabilities (32.6M) exceed total assets (25M)
EPS of -6.17 on 7M shares means massive dilution inevitable - any financing at this level destroys existing shareholders
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage KALA's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Binary outcome: dilutive financing or partnership required within 6 months to avoid insolvency
- Cash burn of 32M/year vs 21M cash
- 28.4M current debt maturing
- No revenue to service obligations
Valuation Context
Caveats
Public Strategies Rankings
See how Kala Bio Inc ranks across different investment strategies.
Leverage KALA's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
KALA Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$1.15M | — | ||
$9.99M | — | ||
0.00 | — | ||
$0 | — | ||
$-5.64 | — | ||
0% | 0.0% | — | |
0% | 0.0% | — | |
$-32.12M | — | ||
0% | — | ||
Beta 5Y (Monthly) | unknown | — |
KALA Dividend History
KALA Stock Splits
KALA SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
11/19/25 | 09/30/25 | 10-Q | |
08/08/25 | 06/30/25 | 10-Q | |
05/14/25 | 03/31/25 | 10-Q | |
03/31/25 | 12/31/24 | 10-K | |
11/12/24 | 09/30/24 | 10-Q | |
08/06/24 | 06/30/24 | 10-Q | |
05/14/24 | 03/31/24 | 10-Q | |
03/29/24 | 12/31/23 | 10-K | |
11/13/23 | 09/30/23 | 10-Q | |
08/04/23 | 06/30/23 | 10-Q | |
05/09/23 | 03/31/23 | 10-Q | |
03/03/23 | 12/31/22 | 10-K | |
11/08/22 | 09/30/22 | 10-Q | |
08/11/22 | 06/30/22 | 10-Q | |
05/16/22 | 03/31/22 | 10-Q | |
03/29/22 | 12/31/21 | 10-K | |
11/15/21 | 09/30/21 | 10-Q | |
08/05/21 | 06/30/21 | 10-Q | |
05/05/21 | 03/31/21 | 10-Q | |
02/25/21 | 12/31/20 | 10-K | |
11/05/20 | 09/30/20 | 10-Q | |
08/06/20 | 06/30/20 | 10-Q | |
05/07/20 | 03/31/20 | 10-Q | |
02/12/20 | 12/31/19 | 10-K | |
11/07/19 | 09/30/19 | 10-Q | |
08/06/19 | 06/30/19 | 10-Q | |
05/09/19 | 03/31/19 | 10-Q | |
03/12/19 | 12/31/18 | 10-K | |
11/08/18 | 09/30/18 | 10-Q | |
08/09/18 | 06/30/18 | 10-Q | |
05/10/18 | 03/31/18 | 10-Q | |
04/02/18 | 12/31/17 | 10-K | |
11/07/17 | 09/30/17 | 10-Q | |
08/31/17 | 06/30/17 | 10-Q | |
07/20/17 | 03/31/17 | 424B4 | |
07/20/17 | 12/31/16 | 424B4 | |
11/07/17 | 09/30/16 | 10-Q | |
08/31/17 | 06/30/16 | 10-Q | |
07/20/17 | 03/31/16 | 424B4 |